Currently, many clinical trials on various immunotherapy agents and other targeted therapies, such as HER2 antibody–drug conjugates, are still ongoing to identify effective treatments for advanced or recurrent cervical cancer. This evidence concerns the gene ERBB2 and cervical carcinoma.